Hyperparathyroidism and Bone Loss: When PTH Is Driving Your Osteoporosis
Primary hyperparathyroidism affects roughly 1 in 1,000 adults, with prevalence rising sharply after age 50. The hallmark is mildly elevated calcium and inappropriately elevated parathyroid hormone (PTH). The bone effect is real and progressive: chronic PTH excess strips calcium from cortical bone, particularly affecting the distal radius and femoral neck. The diagnosis is often delayed because the symptoms are nonspecific and the lab abnormality is mild.
Who should be tested
Anyone with osteoporosis, particularly if BMD loss is preferentially at cortical sites (forearm, femoral neck) rather than trabecular (lumbar spine). Anyone with kidney stones. Unexplained fatigue, depression, or cognitive complaints with even mildly elevated serum calcium. Family history of multiple endocrine neoplasia. The workup is simple: serum calcium, ionized calcium if available, PTH, 24-hour urine calcium, and 25-hydroxyvitamin D.
What the lab pattern looks like
Classic primary hyperparathyroidism: high or upper-normal calcium with inappropriately elevated or even normal PTH. PTH should be suppressed when calcium is high; in primary hyperparathyroidism it is not. Vitamin D is often low, which can mask the calcium elevation. 24-hour urinary calcium is usually elevated (helps distinguish from familial hypocalciuric hypercalcemia).
What the bone effect looks like
On DEXA: disproportionate loss at the distal one-third radius (forearm) compared to lumbar spine. Total hip and femoral neck are intermediate. In severe long-standing disease, the radius can show T-scores worse than -3.5 while the spine remains modestly affected. This pattern alone should prompt PTH testing.
Treatment
Parathyroidectomy — surgical removal of the offending parathyroid adenoma — is the definitive treatment. After successful surgery, bone density improves substantially: 10-20% increases at the lumbar spine over 1-2 years are common; smaller increases at the hip and radius. For patients not undergoing surgery (older patients, mild disease), bisphosphonate therapy can blunt bone loss. Vitamin D repletion is essential before surgery — surgery on vitamin-D-deficient patients can produce profound post-operative hypocalcemia.
Indications for surgery
Age under 50. Symptomatic disease (kidney stones, fractures, severe symptoms). Serum calcium more than 1 mg/dL above upper normal. Significant osteoporosis or vertebral fracture. Reduced kidney function. The guidelines have evolved toward earlier surgery as the procedure has become more refined and minimally invasive.
After surgery
Bone density gain peaks at 1-2 years post-surgery. Standard osteoporosis maintenance — calcium, vitamin D, weight-bearing exercise, resistance training — continues. DEXA every 1-2 years to track recovery. Most patients without other risk factors return to age-appropriate BMD trajectories.
Frequently asked questions
How common is primary hyperparathyroidism?
Roughly 1 in 1000 adults, with prevalence 4-5 fold higher in women than men, and rising sharply after age 50. It is the third most common endocrine disorder after diabetes and thyroid disease.
Will treating hyperparathyroidism reverse my osteoporosis?
Often substantially. Bone density gains of 10-20% at the spine in the 2 years post-parathyroidectomy are typical. Recovery is less complete at cortical sites.
Can vitamin D supplementation alone fix mild hyperparathyroidism?
No — but vitamin D deficiency frequently coexists and masks the diagnosis. Repleting vitamin D often unmasks the calcium elevation and clarifies the picture.
Should I avoid calcium if I have hyperparathyroidism?
No — moderate calcium intake (1000-1200 mg per day from food) is appropriate. Severe restriction worsens secondary problems. The treatment is the parathyroid itself, not dietary calcium restriction.
Related reading: The Bone Density Solution review · Vitamin K2 and bone health
